WaferGen's Q1 Revenues Drop Sharply | GenomeWeb

NEW YORK (GenomeWeb News) – WaferGen Biosystems' revenues for the first quarter of 2012 fell nearly five-fold year over year, the company said in its Form 10-Q filed on Friday with the US Securities and Exchange Commission.

During the three months ended March 31, the Fremont, Calif.-based firm recorded $73,233 in revenues, down from $351,032 a year ago. The sharp dropoff was due to "the absence of sales" of any SmartChip Real-Time PCR Systems in the recently ended quarter, compared to one sale a year ago, WaferGen said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.